Orphazyme Teeters On The Brink As Arimoclomol EU Filing Is Pulled

Danish biotech Orphazyme has withdrawn the EU marketing application for its Niemann-Pick disease type C therapy arimoclomol and all hopes for the drug’s survival now rest on a meeting with the US Food and Drug Administration.